Company profile: Memory Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical discovery and development of drug candidates for central nervous system conditions, including neurological diseases associated with aging (such as Alzheimer's disease) and psychiatric disorders such as schizophrenia.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Memory Pharmaceuticals
Reunion Neuroscience
HQ: Canada
Website
- Description: Provider of clinical-stage therapeutic solutions for underserved mental health conditions, developing RE104, a proprietary short-duration serotonergic psychedelic therapy for postpartum depression and other mental health disorders, and RE200s, discovery candidates structurally similar to classic psychedelics designed to selectively target the serotonin 2A receptor without off-target effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reunion Neuroscience company profile →
Torrey Pines Therapeutics
HQ: United States
Website
- Description: Provider of small molecule drug discovery and development in the United States, with a portfolio comprising candidates from proprietary drug-targeting platforms and in-licensed/acquired programs. As of August 31, 2010, the company's pipeline includes three clinical development programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Torrey Pines Therapeutics company profile →
Quoin Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical products under development addressing major unmet medical needs, including QRX003, a topical lotion in clinical evaluation for Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma; QRX008 for Scleroderma; QRX007 for Netherton Syndrome; and QRX004 for Epidermolysis Bullosa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quoin Pharmaceuticals company profile →
Supernus Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products for central nervous system diseases, developing and commercializing therapies including Qelbree for ADHD; Trokendi XR for epilepsy and migraine prevention; and Oxtellar XR for epilepsy, with pipeline candidates SPN-830 for hypomobility in Parkinson’s disease, SPN-820/821 for treatment-resistant depression, and SPN-817 for severe epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Supernus Pharmaceuticals company profile →
SyntheticMR
HQ: Sweden
Website
- Description: Provider of innovative magnetic resonance imaging software that supports shorter exam times and delivers more information to clinicians. Products include SyMRI NEURO for quantitative MRI with contrast images, tissue segmentation, and volumetric measurements in a single scan; SyMRI MSK for musculoskeletal imaging with quantitative maps and contrast images; and MAGiC, a GE Healthcare version offering customizable MRI imaging solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SyntheticMR company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Memory Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Memory Pharmaceuticals
2.2 - Growth funds investing in similar companies to Memory Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Memory Pharmaceuticals
4.2 - Public trading comparable groups for Memory Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →